Cargando…

Echocardiographic Parameters as Predictors for the Efficiency of Resynchronization Therapy in Patients with Dilated Cardiomyopathy and HFrEF

Cardiac resynchronization therapy (CRT) represents an increasingly recommended solution to alleviate symptomatology and improve the quality of life in individuals with dilated cardiomyopathy (DCM) and heart failure (HF) with reduced ejection fraction (HFrEF) who remain symptomatic despite optimal me...

Descripción completa

Detalles Bibliográficos
Autores principales:	Pescariu, Silvius-Alexandru, Şoşdean, Raluca, Tudoran, Cristina, Ionac, Adina, Pop, Gheorghe Nicusor, Timar, Romulus Zorin, Pescariu, Sorin, Tudoran, Mariana
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	MDPI 2021
Materias:	Article
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8774311/ https://www.ncbi.nlm.nih.gov/pubmed/35054202 http://dx.doi.org/10.3390/diagnostics12010035

Ejemplares similares

Impact of COVID-19 Pandemic on the Implantation of Intra-Cardiac Devices in Diabetic and Non-Diabetic Patients in the Western of Romania
por: Pescariu, Silvius Alexandru, et al.
Publicado: (2021)

Single-Pass VDD Pacing Lead for Cardiac Resynchronization Therapy: A Reliable Alternative
por: Pescariu, Silvius-Alexandru, et al.
Publicado: (2021)

The Challenges of Cardiac Resynchronization Therapy in Patients with Dilated Cardiomyopathy and Persistent Left Superior Vena Cava: A Case Report and Concise Literature Review
por: Pescariu, Silvius Alexandru, et al.
Publicado: (2023)

Evolution of Echocardiographic Abnormalities Identified in Previously Healthy Individuals Recovering from COVID-19
por: Tudoran, Cristina, et al.
Publicado: (2022)

Cardiovascular Abnormalities and Mental Health Difficulties Result in a Reduced Quality of Life in the Post-Acute COVID-19 Syndrome
por: Giurgi-Oncu, Catalina, et al.
Publicado: (2021)

Evidence of Pulmonary Hypertension after SARS-CoV-2 Infection in Subjects without Previous Significant Cardiovascular Pathology
por: Tudoran, Cristina, et al.
Publicado: (2021)

Alterations of Left Ventricular Function Persisting during Post-Acute COVID-19 in Subjects without Previously Diagnosed Cardiovascular Pathology
por: Tudoran, Mariana, et al.
Publicado: (2021)

Factors Influencing the Evolution of Pulmonary Hypertension in Previously Healthy Subjects Recovering from a SARS-CoV-2 Infection
por: Tudoran, Cristina, et al.
Publicado: (2021)

Benefits of peritoneal ultrafiltration in HFpEF and HFrEF patients
por: Grossekettler, Leonie, et al.
Publicado: (2020)

Locomotor and respiratory muscle abnormalities in HFrEF and HFpEF
por: Mangner, Norman, et al.
Publicado: (2023)

The prevalence, predictors, and outcomes of spontaneous echocardiographic contrast or left ventricular thrombus in patients with HFrEF
por: Zhou, Xiaodong, et al.
Publicado: (2021)

Different determinants of exercise capacity in HFpEF compared to HFrEF
por: Batalli, Arlind, et al.
Publicado: (2017)

Aiming at harmony. Comparing and contrasting International HFrEF Guidelines
por: Tomasoni, Daniela, et al.
Publicado: (2022)

Getting ahead of the game: in-hospital initiation of HFrEF therapies
por: Biegus, Jan, et al.
Publicado: (2022)

Mortality and Morbidity in HFrEF, HFmrEF, and HFpEF Patients with Diabetes in the Middle East
por: Al-Jarallah, Mohammed, et al.
Publicado: (2020)

A horse of a different colour: distinct mechanisms of HFpEF and HFrEF
por: Louch, William E.
Publicado: (2020)

Echocardiographic evolution of pulmonary hypertension in female patients with hyperthyroidism
por: Tudoran, Cristina, et al.
Publicado: (2018)

Neprilysin in HFrEF: Differential Regulation of Tissue Versus Circulating Neprilysin
por: Chen, Horng H., et al.
Publicado: (2020)

Empagliflozin and HFrEF: Known and Possible Benefits of NHE1 Inhibition
por: Jun, Seungho, et al.
Publicado: (2019)

Association of Depression Symptoms and Biomarkers of Risk on Clinical Outcomes in HFrEF
por: Sherwood, Andrew, et al.
Publicado: (2023)

Corrigendum to: Aiming at harmony. Comparing and contrasting International HFrEF Guidelines
Publicado: (2023)

Quality of life questionnaire predicts poor exercise capacity only in HFpEF and not in HFrEF
por: Ahmeti, Artan, et al.
Publicado: (2017)

Prevalence of Prediabetes and Undiagnosed Diabetes in Patients with HFpEF and HFrEF and Associated Clinical Outcomes
por: Kristensen, Søren L., et al.
Publicado: (2017)

Myocardial phenotypes and dysfunction in HFpEF and HFrEF assessed by echocardiography and cardiac magnetic resonance
por: Berlot, Bostjan, et al.
Publicado: (2019)

Disparate Clinical Characteristics and Prognosis of HFpEF versus HFrEF Phenotype of Diabetic Cardiomyopathy
por: Li, Zheng, et al.
Publicado: (2023)

Large Animal Models of Heart Failure With Reduced Ejection Fraction (HFrEF)
por: Spannbauer, Andreas, et al.
Publicado: (2019)

Plasma Neprilysin Displays No Relevant Association With Neurohumoral Activation in Chronic HFrEF
por: Prausmüller, Suriya, et al.
Publicado: (2020)

FGF-23 is a biomarker of RV dysfunction and congestion in patients with HFrEF
por: Benes, Jan, et al.
Publicado: (2023)

The vasculature in HFpEF vs HFrEF: differences in contractile protein expression produce distinct phenotypes
por: Lyle, Melissa A., et al.
Publicado: (2019)

Ubiquitin‐proteasome‐system and enzymes of energy metabolism in skeletal muscle of patients with HFpEF and HFrEF
por: Adams, Volker, et al.
Publicado: (2021)

Circulating Relaxin-1 Level Is a Surrogate Marker of Myocardial Fibrosis in HFrEF
por: Simon, Judit, et al.
Publicado: (2019)

Sacubitril/valsartan in HFrEF – Should the aces up our sleeves be played earlier?
por: Boehmer, Andreas A., et al.
Publicado: (2019)

The association between ivabradine and adverse cardiovascular events in acute decompensated HFrEF patients
por: Liao, Chia‐Te, et al.
Publicado: (2021)

Sacubitril/Valsartan vs. Standard Medical Therapy on Exercise Capacity in HFrEF Patients
por: Campanile, Alfonso, et al.
Publicado: (2023)

Cellular and Molecular Differences between HFpEF and HFrEF: A Step Ahead in an Improved Pathological Understanding
por: Simmonds, Steven J., et al.
Publicado: (2020)

Monoamine Oxidase (MAO) Is Expressed at the Level of Mitral Valve with Severe Regurgitation in Hypertrophic Obstructive Cardiomyopathy: A Case Report
por: Lascu, Ana, et al.
Publicado: (2022)

A Practical Guide for the Treatment of Symptomatic Heart Failure with Reduced Ejection Fraction (HFrEF)
por: Reed, Brent N, et al.
Publicado: (2015)

Meta‐analysis of the effects of four factors on the efficacy of SGLT2 inhibitors in patients with HFrEF
por: Qiu, Mei, et al.
Publicado: (2021)

ARNI in HFrEF—One-Centre Experience in the Era before the 2021 ESC HF Recommendations
por: Niemiec, Rafał, et al.
Publicado: (2022)

Chronic Kidney Disease Increases Risk of Incident HFrEF Following Percutaneous Coronary Intervention
por: Lai, Wenguang, et al.
Publicado: (2022)

Cannot write session to /tmp/vufind_sessions/sess_okkkq028q8g242tnsccipgdcmc